Table 5 Multiple cox regression analysis of survival after surgery

Gender (male vs. female)

1.25

0.981–1.593

0.071

Pathology (adeno vs. mix)

1.066

0.864–1.314

0.55

Blood transfusion (no vs. yes)

0.63

0.471–0.843

0.002

Surgical approaches (left thoracotomy vs. transhiatal)

1.365

0.935–1.995

0.107

Tumor size (≤ 4cm vs. > 4cm)

0.728

0.582–0.912

0.006

 Postoperative hospital stays (≤ 10d vs. > 10d)

0.833

0.694–0.999

0.048

  PNLNR (> 1)

1

1

< 0.001

  PNLNR (= 0)

0.561

0.268–1.175

0.126

  PNLNR (≤  1)

0.773

0.507–1.180

0.233

 Perineuronal invasion (no vs. yes)

0.727

0.574–0.922

0.008

Lymphovascular invasion (no vs. yes)

0.899

0.721–1.121

0.346

pTNM stage IV

1

1

0.171

 Stage III

1.166

0.541–2.512

0.694

 Stage II

0.868

0.442–1.707

0.682

 Stage I

0.764

0.426–1.369

0.366

Serum CA199 (U/ml) (<37 vs. ≥37)

0.986

0.784–1.239

0.902

Serum CEA (ng/ml) (<5 vs. ≥5)

0.768

0.623–0.947

0.014

Serum CA242 (U/ml) (<20 vs. ≥20)

0.934

0.707–1.233

0.629

Serum CA125 (U/ml) (<35 vs. ≥35)

0.739

0.490–1.114

0.148

Adjuvant chemotherapy (no vs. yes)

1.478

1.214–1.800

< 0.001